These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 31914330)
1. The adverse-effect profile of lacosamide. Li J; Sun M; Wang X Expert Opin Drug Saf; 2020 Feb; 19(2):131-138. PubMed ID: 31914330 [No Abstract] [Full Text] [Related]
2. A clinical efficacy experience of Lacosamide on sleep quality in patients with Nocturnal Frontal Lobe Epilepsy (NFLE). Mangiardi M; Alfano G Acta Biomed; 2018 Oct; 89(3):397-399. PubMed ID: 30333465 [TBL] [Abstract][Full Text] [Related]
3. Lacosamide induced Brugada I morphology in the setting of septicemia: A case report. Goodnough R; Badea A; Geier C; Lynch KL; LeSaint KT Medicine (Baltimore); 2021 May; 100(18):e25577. PubMed ID: 33950934 [TBL] [Abstract][Full Text] [Related]
4. [Lacosamide associated with high-degree block in a patient with trigeminal neuralgia]. Marin-Gracia M; Cantero-Lozano D; Garces-Anton E; Lopez-Bravo A; Garrido-Fernandez A; Navarro-Perez MP; Santos-Lasaosa S; Garces-Redondo M Rev Neurol; 2018 Mar; 66(6):189-192. PubMed ID: 29537058 [TBL] [Abstract][Full Text] [Related]
5. Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy. Ben-Menachem E; Grebe HP; Terada K; Jensen L; Li T; De Backer M; Steiniger-Brach B; Gasalla T; Brock M; Biton V Epilepsia; 2019 Dec; 60(12):2437-2447. PubMed ID: 31755090 [TBL] [Abstract][Full Text] [Related]
6. Lacosamide for SCN2A-related intractable neonatal and infantile seizures. Flor-Hirsch H; Heyman E; Livneh A; Reish O; Watemberg N; Litmanovits I; Ben Sason Lilli A; Lev D; Lerman Sagie T; Bassan H Epileptic Disord; 2018 Oct; 20(5):440-446. PubMed ID: 30361185 [TBL] [Abstract][Full Text] [Related]
7. The Efficacy and Safety of Lacosamide for Bipolar Depression: A 12-Week Open-Label Pilot Trial. Kishi T; Nomura I; Sakuma K; Okuya M; Oya K; Iwata N J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):204-206. PubMed ID: 33666402 [No Abstract] [Full Text] [Related]
8. Therapeutic Monitoring of Lacosamide in Japanese Patients With Epilepsy: Clinical Response, Tolerability, and Optimal Therapeutic Range. Yamamoto Y; Terada K; Araki Y; Fukushima Y; Imai K; Kagawa Y; Takahashi Y Ther Drug Monit; 2020 Oct; 42(5):754-759. PubMed ID: 32941398 [TBL] [Abstract][Full Text] [Related]
9. Lacosamide in patients with intellectual disability and refractory epilepsy. Kleist A; Kerling F; Hamer H; Winterholler M Acta Neurol Belg; 2019 Sep; 119(3):423-430. PubMed ID: 30840220 [TBL] [Abstract][Full Text] [Related]
10. Lacosamide neurotoxicity associated with concomitant use of sodium channel-blocking antiepileptic drugs: a pharmacodynamic interaction? Novy J; Patsalos PN; Sander JW; Sisodiya SM Epilepsy Behav; 2011 Jan; 20(1):20-3. PubMed ID: 21056937 [TBL] [Abstract][Full Text] [Related]
11. A trial of lacosamide for benign convulsions with gastroenteritis. Numoto S; Kurahashi H; Iwayama H; Okumura A Brain Dev; 2020 Aug; 42(7):551-554. PubMed ID: 32279898 [TBL] [Abstract][Full Text] [Related]
12. Clinical experience combined with therapeutic drug monitoring of lacosamide. Svendsen T; Brodtkorb E; Baftiu A; Lossius MI; Nakken KO; Johannessen SI; Johannessen Landmark C Acta Neurol Scand; 2020 Apr; 141(4):279-286. PubMed ID: 31853958 [TBL] [Abstract][Full Text] [Related]
13. Lacosamide use during breastfeeding: A case report and a literature review. Cercos M; Seqat I; Facile A; Vial T; Auffret M Fundam Clin Pharmacol; 2024 Jun; 38(3):575-578. PubMed ID: 38054544 [TBL] [Abstract][Full Text] [Related]
14. Safety of Intravenous Push Lacosamide Compared With Intravenous Piggyback at a Tertiary Academic Medical Center. McLaughlin K; Carabetta S; Hunt N; Schuler BR; Ting C; Tran LK; Szumita PM; Anger KE Ann Pharmacother; 2021 Feb; 55(2):181-186. PubMed ID: 32686466 [TBL] [Abstract][Full Text] [Related]
15. Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience. Chang RS; Lui HKK; Lui HTC; Leung CYW; Leung YHI; Wang YO J Neurol Sci; 2020 Feb; 409():116601. PubMed ID: 31801052 [TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy of the third-generation AEDs: lacosamide, retigabine and eslicarbazepine acetate. Patsalos PN; Berry DJ Expert Opin Pharmacother; 2012 Apr; 13(5):699-715. PubMed ID: 22404663 [TBL] [Abstract][Full Text] [Related]
17. Lacosamide intoxication in attempted suicide. Bauer S; David Rudd G; Mylius V; Hamer HM; Rosenow F Epilepsy Behav; 2010 Apr; 17(4):549-51. PubMed ID: 20171144 [TBL] [Abstract][Full Text] [Related]
18. Clinical experience with using lacosamide for the treatment of epilepsy in a tertiary centre. Kamel JT; DeGruyter MA; D'Souza WJ; Cook MJ Acta Neurol Scand; 2013 Mar; 127(3):149-53. PubMed ID: 22845761 [TBL] [Abstract][Full Text] [Related]
20. The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting. Sanmartí-Vilaplana F; Díaz-Gómez A Epilepsy Behav; 2018 Feb; 79():130-137. PubMed ID: 29287216 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]